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years at a rate of 6.9 visits/1000 persons annually (95%CI: 5.1,
8.7) compared to children 5–17 years at 8.5 visits/1000 persons
annually (95%CI: 5.6, 11.3). Visits to ofﬁce-based physicians,
hospital emergency departments and outpatient departments
accounted for 85%, 11% and 5% of visits, respectively. 
Antibiotics were prescribed at 2.5 million visits (38% of encoun-
ters) at an estimated cost of $93 million. Broad-spectrum 
antibiotics prescribed at 39% of visits where an antibiotic was
prescribed accounted for $59 million of the total cost for antibi-
otics. Combined visit and antibiotic costs for the group totaled
$441 million. CONCLUSIONS: Prescribing of antibiotics for
inﬂuenza is widespread, increases medical costs and may con-
tribute to antibiotic resistance. Increased use of vaccination 
and viral testing could reduce antibiotic use and result in cost
savings.
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OBJECTIVES: To evaluate the costs and outcomes of extended-
release clarithromycin versus clarithromycin immediate-release
for outpatients with bacterial lower respiratory tract infections
(LRTIs, community-acquired pneumonia and acute exacerba-
tions of chronic bronchitis). METHODS: We developed a 
decision-analysis model comparing extended-release clar-
ithromycin with immediate-release for LRTIs. Treatment success
and adverse event (AE) rates were derived from weighted aver-
ages of identiﬁed published studies that included dichotomous
variables for cure vs. failure (16 immediate-release studies, 4
extended-release). Costs were standard US values. The model
included the acute antibiotic treatment period (start of ﬁrst-line
therapy through completion of second-line therapy, if applica-
ble). The model measured the proportion of patients cured on
ﬁrst- and second-line therapy, patients discontinuing due to AEs
and lack of efﬁcacy, and physician, antibiotic, and total costs per
episode. RESULTS: More patients achieved clinical cure with
clarithromycin extended-release (83.9%) than with clar-
ithromycin immediate-release (72.8%); AE discontinuation rates
were lower for the extended-release group (2.4% versus 4.9%
for the immediate-release group). Total costs with clarithromycin
extended-release were $32 (16%) less than total costs for imme-
diate-release. Sensitivity analyses indicated that the model is
robust to changes in cure and AE discontinuation rates within
reasonable ranges. Incorporating greater treatment adherence for
extended-release (once-daily) versus immediate-release (twice-
daily) therapy resulted in greater cost savings for clarithromycin
extended-release. CONCLUSIONS: Clarithromycin extended-
release is cost saving compared with clarithromycin immediate-
release for LRTIs, using base-case results. The model did not
include hospitalization, which is uncommon in mild to moder-
ate LRTIs; addition of hospitalizations is likely to demonstrate
additional costs savings with clarithromycin extended-release.
These differences in clinical and economic results are important
in that extended-release therapy can lead to improved patient
outcomes with decreased costs. Further research is needed to
determine the cause and impacts of these differences in efﬁcacy
and tolerability.
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OBJECTIVE: To do a cost-effectiveness analysis of the intro-
duction of meningococcal vaccine type C (NeisVac-CTM) in Por-
tugal. METHODS: Model: The study compared vaccine with no
vaccination for a cohort of 100.000 for lifetime using a Markov
model. Scenarios for age of vaccine administration: children with
less than one year of age, children with one year of age and chil-
dren with two years of age. The outcomes measured were avoid-
able cases, avoidable death, avoidable disability and avoidable
years of life lost. RESULTS: For the case base studied the cost
per year of life gained (or lost year of prevented life) for the
NeisVac-CTM was 6372€ for vaccination administer after the ﬁrst
year of life and of 12,635€ for vaccination administer during the
ﬁrst year of life. Difference is explained by the need of two doses
of vaccine during the ﬁrst year of life and only one for the other
scenario. These costs includes the cost of vaccines, the effect and
consequences of vaccines in the consumption of resources of the
health system (hospital, outpatients, medicines, exams, etc.),
direct costs for the State other than of the health system (support
of the Social Welfare and the deﬁcient ones) and the indirect costs
generated by the effect of the disease in the productivity lost by
the families in the case of children or of the self in the case of
disease while in active labor age. Sensitivity analysis showed the
robustness of these values. CONCLUSIONS: Compared with
other interventions routinely done by the National Health
Service the administration of the of the NeisVac-CTM it can be
considered cost-effective for the Portuguese population.
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OBJECTIVE: This study examines the beneﬁt of physician pro-
ﬁling on cost and utilization of antibiotics. METHODS: General
Practitioners, Family Practitioners, Internists and Pediatricians
were sent an education tool regarding the appropriate use of
antibiotics for the treatment of respiratory illnesses for the
2000–01, 2001–02 and 2002–03 seasons. Physicians who pre-
scribed greater than 60 antibiotics in the previous year also
received a proﬁle of their ﬁrst line antibiotic use. The average
ingredient cost per prescription for proﬁled vs. non-proﬁled
physicians was used to determine the impact of physician pro-
ﬁling on antibiotic prescribing behavior. Physicians were also
surveyed during the 2000/01 season on the usefulness of the edu-
cation tool and the proﬁle. RESULTS: Approximately seventeen
thousand physicians were targeted for each season. The ingredi-
ent cost per prescription for ﬁrst line antibiotics was signiﬁcantly
lower for proﬁled (N = 3286) vs. non proﬁled physicians in all
three seasons: $5.19 vs. $5.31 (p < 0.0001) for season 1; $6.29
vs. $6.57 (p < 0.0001) for season 2; and $8.39 vs. $8.57 (p =
0.0003) for season 3. The ingredient cost per prescription was
also lower for second line antibiotics in the proﬁled vs. non-pro-
ﬁled groups for each consecutive season: $55.35 vs. $67.09 (p =
0.057), $56.53 vs. $57.35 (p < 0.0001), and $56.58 vs. $57.22
(p = 0.0001), respectively. Out of the 4.1% of physicians who
responded to the program survey, 84% agreed that the infor-
mation in the education tool was informative and useful. Seventy
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eight percent would consider the information when prescribing.
Seventy-ﬁve percent of the proﬁled physicians who responded
agreed that the proﬁles were informative and useful, and 67%
would consider the information in their prescribing decisions.
CONCLUSION: Providing antibiotic prescribing proﬁles for
physicians may inﬂuence prescribing patterns and maintain cost
in a managed care setting.
PIN28
MEDICOECONOMIC EVALUATION OF OUTPATIENT
MANAGEMENT OF INFANTILE BRONCHIOLITIS IN FRANCE
Vainchtock A1,Trichard M2, Chaufferin G2, Duru G3,
Nicoloyannis N4, Stagnara J5
1GYD Institut Groupe IMS Health, Lyon, France; 2BOIRON
Laboratories, Sainte-Foy-Lès-Lyon, France; 3Claude Bernard University,
Villeurbanne, France; 4Lyon 2 University, Bron, France; 5Paediatrician,
Lyon, France
OBJECTIVES: To compare—in terms of effectiveness and
costs—outpatient management of infantile bronchiolitis by
homeopathic GPs vs allopathic GPs vs paediatricians.
METHODS: A 6-month prospective, “real-world” study was
carried out by setting up 3 observatories with: homeopathic GPs,
allopathic GPs and paediatricians recruited by sample-drawing.
Patients aged between 3 and 24 months, consulting for ﬁrst bout
of acute bronchiolitis since birth, who had not yet received treat-
ment and who did not require immediate hospitalisation were
included. Effectiveness (number and duration of bouts, number
of complications, persistence of bronchial obstruction), direct
medical costs (from the French Health Insurance and societal
perspectives) and indirect costs (sick leaves) were assessed. The
statistical analysis was performed after matching patients to have
comparable patients. RESULTS: One hundred seventeen, 150
and 253 patients were respectively included by 38 homeopathic
GPs, 59 allopathic GPs and 95 paediatricians. At the end of the
study, there were: no signiﬁcant differences between the man-
agement by homeopathic GPs vs allopathic GPs on effectiveness
criteria; no signiﬁcant differences between the management by
homeopathic GPs vs paediatricians in terms of number of bouts,
persistence of bronchial obstruction but signiﬁcant shorter dura-
tion of bouts (4.4 vs 6.6 days) and less complications (0.20 vs
0.40 complication/patient) in the homeopathic group. In Health
Insurance perspective, the management by homeopathic GPs was
signiﬁcantly less expensive than the management by allopathic
GPs and paediatricians (116, 146, 217 €/patient respectively). In
the societal perspective, the management by homeopathic GPs
was signiﬁcantly less expensive than the management by paedi-
atricians (215 vs 361 €/patient) but equivalent to the manage-
ment by allopathic GPs. Homeopathic GPs prescribed equivalent
number of sick leaves to paediatricians but signiﬁcantly less than
allopathic GPs. CONCLUSION: These results could help public
policy makers and practitioners in providing new available data
concerning the outpatient management and cost of infantile
bronchiolitis, that is a public health concern in France.
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OBJECTIVES: Inﬂuenza infection is a major cause of illness,
morbidity and mortality throughout the world, mainly among
the elderly. Since vaccination has proven to be effective in the
reduction of all acute complications, deciding whether to imple-
ment a vaccination campaign, and which vaccine(s) to prescribe
is an important task. The aim of this work is to build a decision
model, which allows the decision-makers to evaluate the possi-
ble results under different scenarios, and to choose the decision
associated to the highest expected utility, in terms of incremen-
tal cost effectiveness ratio (ICER). METHODS: The analysis is
based on the Bayesian Networks. We developed a network that
combines information from an observational study conducted in
Pianiga (Italy) from a group of GPs (Family Medicine Group),
with literature and experts data. This information was used to
create a graph model, which encodes the set of conditional inde-
pendencies among the variables. The probabilities of the relevant
events (mortality and resources consumption) are calculated
using the network. A (dis)utility function, represented by direct
costs, is associated to the decision of implementing or not the
vaccination campaign with a given vaccine. The ICER is then
derived for several possible scenarios. RESULTS: The MF59
vaccine proves to be more cost-effective, as compared to both
the non-vaccination and the standard vaccine. This result is con-
sistent through several scenarios, built upon varying parameters
such as coverage and attack rates. In the basic scenario, obtained
by observed data, MF59 allows a saving of 16,444€ per death
averted, with respect to standard vaccine, and a saving of 
2718 € per death averted as compared to non vaccination. CON-
CLUSIONS: Using Bayesian Networks can help structure the
decision problem and allow for a direct multivariate stochastic
sensitivity analysis. The use this tool is in our opinion highly
valuable, yet not established, in health economics.
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OBJECTIVES: In this observational study, we analyzed the
minimum basic data sets (MBDS) together with the associated
medication costs, relating to stays from 11 hospitals. We focused
on Pneumonia stays considering the effect of antibiotic treatment
(SDT versus parenteral therapy), stay parameters and patient
characteristics on length of stay (LOS) and the resulting antibi-
otic national insurance cost. METHODS: Belgian hospitals 
register case mix data for admissions in MBDS: we extracted
anonymous medical data and prescribed drug cost data from
stays of 11 peripheral Flemish hospitals (during 2001). MBDS
contains ICD-9-CM codes and performed procedures as well as
other stay parameters (severity, risk of mortality, LOS), patient
characteristics (age, gender) and drug utilization data. Data were
stored in MS Access 2000 and analyzed in SPSSWIN 12.0. Stays
were considered independent; LOS and cost data were log trans-
formed to obtain homoscedasticity. RESULTS: The database
contained 302,704 patient stays: 6742 relate to pneumonia.
Pneumococcus pneumonia was reported in 472 stays (461
patients). Mean (SD) LOS was 16.3 (21.9) days; 89 % of the
admissions were unscheduled. Mortality was 8.1%. The 
frequency of antibiotic use was: Amoxicillin-Clavulanate 
63.9%, cephalosporins third generation 30,8%, quinolones
16.8%, cephalosporins second generation 15.7%, macrolides
15.7%, aminoglycosides 15.3%. In 48,9% one, in 25% two and
in 12% three AB-classes were administered. 37.7% SDT therapy
was used. LOS was unaffected by SDT but there was a signiﬁ-
cant effect (p < 0.001 Anova) of age, stay severity and the
